Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IRWD vs VNDA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRWD Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

IRWD Overall Winner 6-Pillar Tally: IRWD 6 – 0 VNDA Matrix Metrics: IRWD 7 – 3 VNDA

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IRWD carries a Unified Composite Score of 34.8/100 (SELL) at $4.84 (12.3x Forward P/E, 62.9% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin).

  • Composite vs. Pillar Nuance: While VNDA currently prints a higher short-term Unified Composite Score (49.0/100 HOLD vs. IRWD 34.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -77.6% operating margin) and revenue trajectory (+9.0% vs. +24.1% YoY).
  • Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 75.5); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IRWD vs VNDA
IRWD NASDAQ Head-to-Head Winner
Ironwood Pharmaceuticals, Inc. - Class A
Pharmaceutical Preparations
$4.84
+0.31% 1D
Market Cap $802.9M
TTM Revenue $400M
Forward P/E 12.3x
Beta / 30D Vol 1.38β · 54% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 50.0 Fund 33.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 76
RSI-14: 75.5 · SMA20: $4.00 · SMA50: $3.98
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46

6-Pillar Scorecard Institutional Category Breakdown (IRWD 6 – 0 VNDA)

Columns: Metric · IRWD · VNDA
1. Valuation Multiples IRWD
Forward P/E 12.3x 103.1x
Trailing P/E 5.4x 103.1x
PEG Ratio N/M 2.23x
EV / Revenue 2.6x 0.9x
2. Growth & Scale IRWD
Revenue Growth (YoY) +9.0% +24.1%
Earnings Growth (YoY) +57.0% -95.9%
TTM Revenue (USD) $400M $229M
Market Cap $802.9M $238.9M
3. Profitability & Quality IRWD
Gross Margin 76.4% 93.6%
Operating Margin 62.9% -77.6%
Net Profit Margin 37.4% -119.9%
Return on Equity (ROE) -574.7% -82.5%
4. Balance Sheet & Cash Flow IRWD
Cash Generation (TTM) $205M -$150M
Cash Flow Margin 51.3% -65.4%
Net Cash / Leverage $250M Net Debt $40M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IRWD
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 63.1% (6th %ile) 163.3% (75th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IRWD
OpEx & R&D Intensity 13.5% of Rev ($54M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IRWD (7) vs VNDA (3)
Institutional Metric IRWD VNDA Criterion Row Edge
Market Capitalization
Scale
$802.9M $238.9M Larger Scale IRWD
Trailing P/E Ratio
Valuation
5.4x 103.1x Lower Multiple IRWD
Forward P/E Ratio
Valuation
12.3x 103.1x Lower Multiple IRWD
Revenue Growth (YoY)
Growth
+9.0% +24.1% Higher Growth VNDA
Operating Margin (TTM)
Profitability
62.9% -77.6% Higher Margin IRWD
Net Profit Margin
Profitability
37.4% -119.9% Higher Margin IRWD
Return on Equity (ROE)
Capital Efficiency
-574.7% -82.5% Higher ROE VNDA
52-Week Range Position
Momentum
67% ($3–$6) 4% ($4–$10) Stronger Trend IRWD
Beta / 30D Volatility
Risk Regime
1.38β · 54% Vol 1.25β · 61% Vol Lower Realized Risk IRWD
Unified Institutional Score
Composite Signal
34.8 / 100 (SELL) 49.0 / 100 (HOLD) Higher Composite VNDA
Trailing 12M Revenue (USD)
Operating Scale
$400M $229M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
76.4% 93.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.6x EV/Rev 2.23x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$205M ($250M Net Debt) -$150M ($40M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IRWD +44.26 pp
IRWD: +38.43% · VNDA: -5.83%
3M Horizon IRWD +42.65 pp
IRWD: +12.41% · VNDA: -30.24%
6M Horizon IRWD +76.01 pp
IRWD: +38.43% · VNDA: -37.58%
1Y Horizon IRWD +56.33 pp
IRWD: +43.77% · VNDA: -12.56%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IRWD Revenue VNDA Revenue IRWD Op. Margin VNDA Op. Margin Margin Leader
FY2018 $350M $190M -43.5% 11.3% VNDA
FY2019 $430M $230M 28.0% 10.0% IRWD
FY2020 $390M $250M 36.7% 11.0% IRWD
FY2021 $410M $270M 56.1% 15.7% IRWD
FY2022 $410M $250M 61.0% 2.5% IRWD
FY2023 $440M $190M -213.5% -7.2% VNDA
FY2024 $350M $200M 26.5% -20.5% IRWD
FY2025 $300M $220M 33.3% -70.0% IRWD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IRWD CONSOLIDATION
134d in phase · OBV ACCUMULATION
Current IV 63.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IRWD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IRWD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $802.9M market capitalization and 62.9% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($54M)
90D Engineering Disclosures 0 Published
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IRWD vs VNDA Key Questions & Quantitative Answers

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IRWD carries a Unified Composite Score of 34.8/100 (SELL) at $4.84 (12.3x Forward P/E, 62.9% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin). Composite vs. Pillar Nuance: While VNDA currently prints a higher short-term Unified Composite Score (49.0/100 HOLD vs. IRWD 34.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -77.6% operating margin) and revenue trajectory (+9.0% vs. +24.1% YoY). Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 75.5); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRWD leads the Growth & Scale pillar: IRWD posts +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin), compared with VNDA at +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IRWD cumulative revenue shifted -14.3% while VNDA shifted +15.8%. In operating R&D and SG&A reinvestment, IRWD deploys 13.5% of Rev ($54M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VNDA.

IRWD screens cheaper on headline valuation multiples. IRWD trades at 12.3x Forward P/E, 5.4x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin), whereas VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IRWD (-574.7% ROE) versus VNDA (-82.5% ROE) capital efficiency.

In options market volatility and institutional positioning, IRWD carries 63.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.38β · 54% Vol realized risk). By comparison, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.